Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$7.94 USD
+0.24 (3.12%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $7.80 -0.14 (-1.76%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 395 | 551 | 518 | 267 | 75 |
Receivables | 3 | 3 | 9 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 40 | 16 | 8 | 2 | 1 |
Total Current Assets | 438 | 570 | 535 | 269 | 76 |
Net Property & Equipment | 87 | 88 | 65 | 26 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 89 | 2 | 2 | 2 | 0 |
Deposits & Other Assets | 7 | 8 | 9 | 1 | 1 |
Total Assets | 654 | 701 | 610 | 299 | 101 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 1 | 0 |
Accounts Payable | 4 | 5 | 3 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 47 | 33 | 32 | 10 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 36 | 57 | 10 | 10 | 0 |
Total Current Liabilities | 93 | 100 | 47 | 23 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 4 | 3 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 1 | 11 | 12 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 51 | 70 | 7 | 17 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 190 | 215 | 67 | 57 | 25 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 448 | 201 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,431 | 1,125 | 943 | 7 | 2 |
Retained Earnings | -968 | -640 | -400 | -214 | -127 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 463 | 486 | 543 | 242 | 77 |
Total Liabilities & Shareholder's Equity | 654 | 701 | 610 | 299 | 101 |
Total Common Equity | 463 | 486 | 543 | -206 | -124 |
Shares Outstanding | 234.20 | 191.00 | 170.20 | NA | NA |
Book Value Per Share | 1.98 | 2.54 | 3.19 | 0.00 | 0.00 |
Fiscal Year End for Recursion Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 395 | 390 | 409 | 474 |
Receivables | NA | 3 | 3 | 3 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 40 | 18 | 19 | 16 |
Total Current Assets | NA | 438 | 411 | 431 | 492 |
Net Property & Equipment | NA | 87 | 86 | 90 | 90 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 89 | 92 | 103 | 2 |
Deposits & Other Assets | NA | 7 | 8 | 8 | 8 |
Total Assets | NA | 654 | 631 | 667 | 627 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 1 | 1 | 1 |
Accounts Payable | NA | 4 | 4 | 2 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 47 | 40 | 33 | 25 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 36 | 44 | 73 | 58 |
Total Current Liabilities | NA | 93 | 94 | 114 | 92 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 2 | 4 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 1 | 1 | 1 | 1 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 51 | 32 | 57 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 190 | 193 | 198 | 197 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,431 | 1,313 | 1,251 | 1,135 |
Retained Earnings | NA | -968 | -875 | -782 | -705 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 463 | 438 | 469 | 430 |
Total Liabilities & Shareholder's Equity | NA | 654 | 631 | 667 | 627 |
Total Common Equity | 0 | 463 | 438 | 469 | 430 |
Shares Outstanding | 234.60 | 234.20 | 216.30 | 206.70 | 192.20 |
Book Value Per Share | 0.00 | 1.98 | 2.02 | 2.27 | 2.24 |